Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15596862 | 0.82 | ALDH1A1 (0.49) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL14997976 | 0.82 | ALDH1A1 (0.49) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL12619318 | 0.82 | RAB9A (0.49) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL12653306 | 0.82 | NPC1 (0.50) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL257873 | 0.79 | ALDH1A1 (0.69) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL10381933 | 0.79 | THRB (0.56) | RAB9AALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL10833499 | 0.78 | ALDH1A1 (0.44) | NPC1RAB9AALDH1A1MAPK1MAPT | |
| SCHEMBL13604922 | 0.78 | ALDH1A1 (0.42) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL8737052 | 0.75 | KDM4E (0.66) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL6165864 | 0.75 | ALDH1A1 (0.78) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120071653-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | NPC1 4531/4885RAB9A 2919/4885ALDH1A1 2454/4885 |
| US-20120071653-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | NPC1 1431/4885RAB9A 523/4885ALDH1A1 541/4885 |
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | NPC1 1431/4885RAB9A 523/4885ALDH1A1 541/4885 |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | NPC1 4456/4885RAB9A 2899/4885ALDH1A1 2168/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | NPC1 2394/4885RAB9A 661/4885ALDH1A1 4310/4885 |
| US-20140206865-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | NPC1 1431/4885RAB9A 523/4885ALDH1A1 541/4885 |
| US-20130144056-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | NPC1 1431/4885RAB9A 523/4885ALDH1A1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.